top of page
  • Writer's pictureAkthelia News Desk

Akthelia Pharmaceuticals Participates in the LSX Leaders Nordic Congress 2022

Akthelia Pharmaceuticals will attend the LSX, Sept 6-7, 2022 in Copenhagen

REYKJAVIK, Iceland -- 1 Sept, 2022 -- Akthelia Pharmaceuticals, a biopharma company, with a first-in-class immunotherapeutic approach, will attend the 2022 LSX Leaders Nordic Congress in Copenhagen.

To arrange a meeting with CEO Egill Masson, please contact us.



Akthelia Pharmaceuticals is a preclinical-stage biopharma company with a next-generation immunotherapeutic strategy to upregulate the innate immunology of epithelial surfaces. This novel approach has application potential to many areas of medicine and addresses the growing threat of antibiotic bacterial resistance (AMR) worldwide.

Akthelia’s lead therapeutic program upregulates the innate immunology in the GI tract, blocking leakage of microbiota to improve outcomes in cancer care through reducing the risk of neutropenia, a common and severe complication in chemotherapy and immunocompromised patients.



Akthelia Pharmaceuticals Grandagarði 16 101 Reykjavik Iceland


bottom of page